Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

被引：180

作者：

Petrov, Kimberly G. ^{[1
]}

Zhang, Yue-Mei ^{[1
]}

Carter, Malcolm ^{[1
]}

Cockerill, G. Stuart ^{[1
]}

Dickerson, Scott ^{[1
]}

Gauthier, Cassandra A. ^{[1
]}

Guo, Yu ^{[1
]}

Mook, Robert A., Jr. ^{[1
]}

Rusnak, David W. ^{[1
]}

Walker, Ann L. ^{[1
]}

Wood, Edgar R. ^{[1
]}

Lackey, Karen E. ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Res Triangle Pk, NC USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 17期

关键词：

ErbB-1 tyrosine kinase inhibitors; ErbB-2 tyrosine kinase inhibitors; EGFR kinase inhibitors; quinazoline; lapatinib;

D O I：

10.1016/j.bmcl.2006.05.090

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：4686 / 4691

页数：6

共 50 条

[31] The Tyrosine Kinase Receptor HER2 (erbB-2) From Oncogenesis to Adipogenesis
Vazquez-Martin, Alejandro
Jose Ortega-Delgado, Francisco
Manuel Fernandez-Real, Jose
Menendez, Javier A.
JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 105 (05) : 1147 - 1152
[32] Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain
Fiorentino, L
Pertica, C
Fiorini, M
Talora, C
Crescenzi, M
Castellani, L
Alemà, S
Benedetti, P
Segatto, O
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (20) : 7735 - 7750
[33] The Prognostic Significance of ErbB-1 (EGFR), ErbB-2 (HER2) and c-MET Overexpression in Resectable Gastric Carcinoma (GC)
Tessier-Cloutier, Basile
Paliga, Aleksandra
Marginean, Horia
Purgina, Bibianna
Jonker, Derek
Marginean, Esmeralda
LABORATORY INVESTIGATION, 2015, 95 : 195A - 195A
[34] Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
Burris, HA
ONCOLOGIST, 2004, 9 : 10 - 15
[35] Discovery and profile of GW572016, a dual reversible EGFR/ErbB-2 tyrosine kinase inhibitor.
Mullin, RJ
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U2 - U2
[36] The Prognostic Significance of ErbB-1 (EGFR), ErbB-2 (HER2) and c-MET Overexpression in Resectable Gastric Carcinoma (GC)
Tessier-Cloutier, Basile
Paliga, Aleksandra
Marginean, Horia
Purgina, Bibianna
Jonker, Derek
Marginean, Esmeralda
MODERN PATHOLOGY, 2015, 28 : 195A - 195A
[37] ErbB-2 amplification, ErbB-1 expression and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study.
Arpino, G
Green, S
Allred, DC
Ravdin, P
Lew, D
Martino, S
Osborne, CK
Elledge, R
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S67 - S67
[38] The prognostic significance of ErbB-1 (EGFR), ErbB-2 (HER2), and c-MET overexpression in resectable gastric carcinoma (GC).
Paliga, Aleksandra
Marginean, Horia
Purgina, Bibianna Maria
Tessier, Basile
Jonker, Derek J.
Marginean, E. Celia
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[39] The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications
Alaoui-Jamali, MA
Paterson, J
Al Moustafa, AE
Yen, L
BIOCHEMISTRY AND CELL BIOLOGY, 1997, 75 (04) : 315 - 325
[40] Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, SC
Lien, HC
Xia, WY
Chen, IF
Lo, HW
Wang, ZQ
Ali-Seyed, M
Lee, DF
Bartholomeusz, G
Fu, OY
Giri, DK
Hung, MC
CANCER CELL, 2004, 6 (03) : 251 - 261

← 1 2 3 4 5 →